EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment
Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More
Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Imugene’s VAXINIA trial shows promising early results for solid tumours
Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the ... Read More
Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC
Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck's KEYTRUDA for first-line treatment of metastatic non-small cell lung ... Read More
ENB Therapeutics completes Phase 1 trial enrollment for ENB-003
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. ... Read More
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More
Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More
PDS Biotechnology gets FDA fast track status for PDS0101
PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More